German biopharma company Omeicos Therapeutics snags Series C funding

Berlin-based Omeicos Therapeutics, a biopharmaceutical company, has secured 17 million euros in Series C funding. Forbion led the round.

2 November 2018•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.